- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05771714
Clinical Performance Evaluation of the CareSuperb™ COVID-19 Antigen Home Test
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, prospective, randomized clinical agreement study to evaluate the sensitivity and specificity of the CareSuperb™ COVID-19 Antigen Home Test when a lay person conducts the test on themselves, or another study participant, as compared to EUA authorized high sensitivity RT-PCR comparator tests.
Patients presenting to the study site for COVID-19 testing who have signed the informed consent and assent, if applicable, and who meet the eligibility criteria will be enrolled in the study. Upon enrollment, the subject will be assigned a unique subject identification (ID) number. After obtaining relevant demographic and medical information, testing will ensue.
The first sample, collected by the clinical research staff, will be for the standard of care (SOC). Results of the SOC test will be used for subject treatment and management. To mitigate any potential bias which may affect the subject's visual interpretation of the CareSuperb™ test result, the study staff will not provide the SOC test results to the subject until after the results of the CareSuperb™ test are read by the subject.
There will be a 15-minute minimum wait period prior to the collection of the second anterior nares swab sample and an additional 15-minute minimum wait period between the second and third sample collection.
For Even numbered subjects, the second sample, collected by a study staff member, will be used for the RT-PCR comparator tests. The third sample will be collected and tested by the lay user, using the CareSuperb™ COVID-19 Antigen Home Test.
For Odd numbered subjects, the second sample will be collected and tested by the lay user using the CareSuperb™ COVID-19 Antigen Home Test. The third sample will be collected by a study staff member and will be used for the RT-PCR comparator tests.
The clinical study staff member will photograph each subject's test cartridge, labeled with their corresponding subject ID number. Additionally, the study staff member will record whether or not they agree with the test result's interpretation by the subject, and if not, why.
The RT-PCR sample will be placed in the provided viral transport medium (VTM) vial and stored in a -70°C freezer until ready for shipment to the central lab.
The comparator samples for RT-PCR testing will be shipped to the central lab weekly, unless directed otherwise by either the sponsor or the Clinical Research Organization (CRO). Specimens should be shipped on dry ice for next day delivery, avoiding weekend delivery. RT-PCR testing will be performed by the central lab and residual samples will be stored. The central lab will report both the qualitative results for each sample, i.e., positive or negative for COVID-19, and the cycle threshold (Ct) value for all positive samples.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33142
- L&A Morales Healthcare, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- An Institutional Review Board (IRB) approved informed consent and assent (if applicable) is signed and dated prior to any study related activities.
- Male and female subjects 2 years of age and older, presenting to the site seeking COVID-19 testing. If symptomatic, symptom onset must be within 5 days of enrollment into the study.
- Subject is willing to provide a self-collected nasal swab sample. (If under the age of 14, the sample will be collected by an adult lay user.)
- Subject is willing to have nasal swabs collected by a member of the study staff.
- Subject agrees to complete all aspects of the study.
Exclusion Criteria:
- Subject is undergoing treatment currently and/or within the past 30 days of study enrollment with medication to treat SARS-CoV-2, which may include but is not limited to Paxlovid, Remdesivir.
- Subject is receiving convalescent plasma therapy for SARS-CoV-2.
- Subject used a nasal wash or nasal aspirate treatment on enrollment day.
- Subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic treatment or therapy, or drug.
- Subjects who report or whose clinical status or history indicates that they take biotin >10 mg per day.
- Subjects who previously enrolled in this study.
- Subject has a visual impairment that cannot be restored with glasses or contact lenses.
- Subject has prior medical or laboratory training.
- Subject has prior knowledge of their current COVID-19 infection status.
- Subject with a history of frequent or difficult to control nosebleeds within the last fourteen (14) days.
- Subject has received a positive COVID-19 test result within the past sixty (60) days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: individuals ages 14 years and older
This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples from individuals ages 14 years and older.
|
At home COVID-19 antigen test kit
|
Experimental: individuals aged 2 to 13 years
This kit is intended for non-prescription home use with self-collected direct anterior nares swab samples. If the subject is under the age of 14, an adult lay-user will collect the sample. |
At home COVID-19 antigen test kit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive percent agreement with sensitivity
Time Frame: within two weeks of study enrollment
|
Compare the positive result between CareSuperb COVID-19 Ag Home Test and three RT-PCR comparators.
|
within two weeks of study enrollment
|
Negative percent agreement with specificity
Time Frame: within two weeks of study enrollment
|
Compare the negative result between CareSuperb COVID-19 Ag Home Test and three RT-PCR comparators.
|
within two weeks of study enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hyeonsuk Kim, Access Bio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-22255-PR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
Clinical Trials on CareSuperb COVID-19 Antigen Home Test Kit
-
Arion BioCSSi Life SciencesCompleted
-
PATHCompleted
-
Arion BioCSSi Life SciencesCompleted
-
Texas Woman's UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Sequenom, Inc.Labcorp Corporation of America Holdings, IncCompletedInfluenza A | RSV Infection | COVID-19 Respiratory Infection | Influenza Type BUnited States
-
BioTeke USA, LLCCSSi Life SciencesCompleted
-
EDP BiotechParagon Rx Clinical, Inc.; iCura Diagnostics, LLCCompleted
-
MP Biomedicals, LLCEDP BiotechCompletedCOVID-19 | SARS-CoV2 InfectionUnited States
-
Polish Society of Disaster MedicineActive, not recruiting